The NLRP3 Inflammasome and COVID-19: Activation, Pathogenesis and Therapeutic Strategies

Overview

Journal Cytokine Growth Factor Rev

Date 2021 Jun 29

PMID 34183243

Citations 75

Authors

Ni Zhao

Bin Di

Li-Li Xu

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), exhibits a wide spectrum of clinical presentations, ranging from asymptomatic cases to severe pneumonia or even death. In severe COVID-19 cases, an increased level of proinflammatory cytokines has been observed in the bloodstream, forming the so-called "cytokine storm". Generally, nucleotide-binding oligomerization domain-like receptor containing pyrin domain 3 (NLRP3) inflammasome activation intensely induces cytokine production as an inflammatory response to viral infection. Therefore, the NLRP3 inflammasome can be a potential target for the treatment of COVID-19. Hence, this review first introduces the canonical NLRP3 inflammasome activation pathway. Second, we review the cellular/molecular mechanisms of NLRP3 inflammasome activation by SARS-CoV-2 infection (e.g., viroporins, ion flux and the complement cascade). Furthermore, we describe the involvement of the NLRP3 inflammasome in the pathogenesis of COVID-19 (e.g., cytokine storm, respiratory manifestations, cardiovascular comorbidity and neurological symptoms). Finally, we also propose several promising inhibitors targeting the NLRP3 inflammasome, cytokine products and neutrophils to provide novel therapeutic strategies for COVID-19.

Citing Articles

Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.

Naiditch H, Betts M, Larman H, Levi M, Rosenberg A Front Immunol. 2025; 15:1376654.

PMID: 40012912 PMC: 11861071. DOI: 10.3389/fimmu.2024.1376654.

COVID-19 Induces Greater NLRP3 Inflammasome Activation in Obese Patients than Other Chronic Illnesses: A Case-Control Study.

DAmico R, Nagashima S, Carstens L, Bertoldi K, Mataruco S, Honorio DAgostini J Int J Mol Sci. 2025; 26(4).

PMID: 40004007 PMC: 11855377. DOI: 10.3390/ijms26041541.

L. alleviates acute lung injury in human A-549 cells by reducing NF-κB and NLRP3 inflammasome signaling.

Hsieh L, Hsieh S, Ping T, Huang Y, Lin S, Chi H Pharm Biol. 2024; 63(1):1-13.

PMID: 39670672 PMC: 11648134. DOI: 10.1080/13880209.2024.2433994.

Inflammatory, Hematological, and Biochemical Biomarkers in COVID-19 Patients.

Ayako R, Patel K, Ndede I, Nordgren J, Larrson M, Mining S Immun Inflamm Dis. 2024; 12(12):e70078.

PMID: 39641395 PMC: 11621974. DOI: 10.1002/iid3.70078.

Itaconate to treat acute lung injury: recent advances and insights from preclinical models.

Wu Q, Li Q, Yang P, Du L Am J Transl Res. 2024; 16(8):3480-3497.

PMID: 39262751 PMC: 11384376. DOI: 10.62347/NUIN2087.

References

Sreeramkumar V, Adrover J, Ballesteros I, Cuartero M, Rossaint J, Bilbao I . Neutrophils scan for activated platelets to initiate inflammation. Science. 2014; 346(6214):1234-8. PMC: 4280847. DOI: 10.1126/science.1256478. View

Shenoy A, Wellington D, Kumar P, Kassa H, Booth C, Cresswell P . GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science. 2012; 336(6080):481-5. DOI: 10.1126/science.1217141. View

Bahadoram M, Keikhaei B, Saeedi-Boroujeni A, Mahmoudian-Sani M . Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?. Naunyn Schmiedebergs Arch Pharmacol. 2021; 394(5):997-1001. PMC: 7792551. DOI: 10.1007/s00210-020-02034-6. View

Yu S, Wang D, Huang L, Zhang Y, Luo R, Adah D . The complement receptor C5aR2 promotes protein kinase R expression and contributes to NLRP3 inflammasome activation and HMGB1 release from macrophages. J Biol Chem. 2019; 294(21):8384-8394. PMC: 6544858. DOI: 10.1074/jbc.RA118.006508. View

Ribeiro D, Oliveira-Giacomelli A, Glaser T, Arnaud-Sampaio V, Andrejew R, Dieckmann L . Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology. Mol Psychiatry. 2020; 26(4):1044-1059. PMC: 7738776. DOI: 10.1038/s41380-020-00965-3. View

Netland J, DeDiego M, Zhao J, Fett C, Alvarez E, Nieto-Torres J . Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology. 2010; 399(1):120-128. PMC: 2830353. DOI: 10.1016/j.virol.2010.01.004. View

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Rogers A, Guan J, Trtchounian A, Hunninghake G, Kaimal R, Desai M . Association of Elevated Plasma Interleukin-18 Level With Increased Mortality in a Clinical Trial of Statin Treatment for Acute Respiratory Distress Syndrome. Crit Care Med. 2019; 47(8):1089-1096. PMC: 6629502. DOI: 10.1097/CCM.0000000000003816. View

10.

Adinolfi E, Giuliani A, De Marchi E, Pegoraro A, Orioli E, Di Virgilio F . The P2X7 receptor: A main player in inflammation. Biochem Pharmacol. 2017; 151:234-244. DOI: 10.1016/j.bcp.2017.12.021. View

11.

Lin L, Xu L, Lv W, Han L, Xiang Y, Fu L . An NLRP3 inflammasome-triggered cytokine storm contributes to Streptococcal toxic shock-like syndrome (STSLS). PLoS Pathog. 2019; 15(6):e1007795. PMC: 6553798. DOI: 10.1371/journal.ppat.1007795. View

12.

Leung Y, Hui L, Kraus V . Colchicine--Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015; 45(3):341-50. PMC: 4656054. DOI: 10.1016/j.semarthrit.2015.06.013. View

13.

Santos R, Sampaio W, Alzamora A, Motta-Santos D, Alenina N, Bader M . The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 2018; 98(1):505-553. PMC: 7203574. DOI: 10.1152/physrev.00023.2016. View

14.

Channappanavar R, Fehr A, Vijay R, Mack M, Zhao J, Meyerholz D . Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016; 19(2):181-93. PMC: 4752723. DOI: 10.1016/j.chom.2016.01.007. View

15.

Katsnelson M, Lozada-Soto K, Russo H, Miller B, Dubyak G . NLRP3 inflammasome signaling is activated by low-level lysosome disruption but inhibited by extensive lysosome disruption: roles for K+ efflux and Ca2+ influx. Am J Physiol Cell Physiol. 2016; 311(1):C83-C100. PMC: 4967136. DOI: 10.1152/ajpcell.00298.2015. View

16.

Ratajczak M, Kucia M . SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells. Leukemia. 2020; 34(7):1726-1729. PMC: 7262681. DOI: 10.1038/s41375-020-0887-9. View

17.

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1):11. PMC: 7068984. DOI: 10.1186/s40779-020-00240-0. View

18.

Purvis G, Collino M, Aranda-Tavio H, Chiazza F, ORiordan C, Zeboudj L . Inhibition of Bruton's TK regulates macrophage NF-κB and NLRP3 inflammasome activation in metabolic inflammation. Br J Pharmacol. 2020; 177(19):4416-4432. PMC: 7484557. DOI: 10.1111/bph.15182. View

19.

Frantzeskaki F, Armaganidis A, Orfanos S . Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks between Inflammation and Coagulation. Respiration. 2016; 93(3):212-225. DOI: 10.1159/000453002. View

20.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View